PHSI3012 10-1 Disorders of Lipid Metabolism #1 (T3L1)

Description

PHSI3012 10-1 Disorders of Lipid Metabolism #1 (T3L1)
Michael Jardine
Quiz by Michael Jardine, updated more than 1 year ago
Michael Jardine
Created by Michael Jardine almost 7 years ago
42
0

Resource summary

Question 1

Question
How many ATPs go where? (btw, "1 ATP" goes before "1ATP")
Answer
  • 2 ATP
  • 2ATP
  • ATP
  • 4 ATP
  • 36 ATP
  • 129 ATP

Question 2

Question
Free fatty acids (NEFA / Non-Esterified Fatty Acids) vs TriAcylGlycerides (/TAGs). [blank_start]__________[blank_end] circulate bound to albumin. [blank_start]__________[blank_end] circulate within [blank_start]__________[blank_end] released from the liver or [blank_start]__________[blank_end] released from the gut.
Answer
  • NEFA
  • TAGs
  • VLDLs
  • Chylomicrons

Question 3

Question
Lipid uptake. Put the three in order (they’re written alphabetically here) [blank_start]__________[blank_end] Cholesterol-rich LDL interact with LDL-R and scavenger receptors; enters lysosomal pathway for hydrolysis; [blank_start]__________[blank_end] Hepatic Lipase and Lipoprotein Lipase reside on endothelial cells to hydrolyse VLDL and Chylomicron TAG to FFAs for uptake; [blank_start]__________[blank_end] TAG-rich VLDL interact with VLDL-R, enters lysosomal pathway where acid lipases hydrolyse TAG.
Answer
  • Stage 3
  • Stage 1
  • Stage 2

Question 4

Question
Familial Lipoprotein Lipase Deficiency is:
Answer
  • Autosomal DOMINANT
  • Autosomal RECESSIVE

Question 5

Question
LPL deficiency causes [blank_start]__________[blank_end], which leads to [blank_start]__________[blank_end].
Answer
  • Accumulation of Chylomicrons
  • Accumulation of LDLs
  • Accumulation of HDLs
  • Accumulation of VLDLs
  • Hypertriglyceridaemia
  • Hypotriglyceridaemia

Question 6

Question
Fatty Acid Metabolism has two major pathways: TriAcylGlycerol metabolism and β-Oxidation. FA uptake is a 2-step process. In which order does it happen?
Answer
  • Transport by FA transporters >> Activation by Acyl-CoA Synthetases
  • Activation by Acyl-CoA Synthetases >> Transport by FA transporters

Question 7

Question
FA activation:
Answer
  • Consumes 1 ATP
  • Is irreversible
  • Is reversible
  • Consumes 2 ATP
  • Consumes 4 ATP
  • Consumes 36 ATP

Question 8

Question
De Novo Fatty Acid Synthesis uses [blank_start]__________[blank_end] (from Glucose and Amino acids) to generate [blank_start]__________[blank_end] as the starting substrate to firstly produce [blank_start]__________[blank_end] (C16:O).
Answer
  • Citrate
  • Acetyl-CoA
  • Malonyl-CoA
  • Palmitate

Question 9

Question
De Novo Fatty Acid Synthesis uses up how many ATP molecules?
Answer
  • 1
  • 2
  • 7
  • 36

Question 10

Question
CPT1 turns Carnitine into FA-Carnitine, allowing it to be uptaken into a cell. This can be blocked by which of the following?
Answer
  • Malonyl-CoA
  • Acetyl-CoA

Question 11

Question
MCD deficiency (and some similar disorders) prevent [blank_start]__________[blank_end] from being turned into [blank_start]__________[blank_end]. This results in [blank_start]__________[blank_end] of CPT1 (and thus [blank_start]__________[blank_end] FA uptake).
Answer
  • Malonyl-CoA
  • Acetyl-CoA
  • Blockage
  • Stimulation
  • Reduces
  • Increases

Question 12

Question
What goes where? (within each box, put the two in alphabetical order)
Answer
  • Adipose-derived Fatty Acids
  • Chylomicron-derived Fatty Acids
  • De novo Lipogenesis
  • Re-esterification
  • Fatty Acid Oxidation
  • TAG Secretion (e.g. VLDL)
Show full summary Hide full summary

Similar

Epithelial tissue
Morgan Morgan
Renal System A&P
Kirsty Jayne Buckley
Physiology / Intro psychology
Molly Macgregor
Carbohydrates, Metabolism & spectrometry
tanitia.dooley
Energy Metabolism
hanngeiss
Introduction to Therapeutic Physical Agents
natalia m zameri
Malignancies
Mark George
PHSI3012 12-1 Diabetes and its Medical Complications (T3L5)
Michael Jardine
PHSI3012 10-2 Disorders of Lipid Metabolism #2 (T3L2)
Michael Jardine
PHSI3012 11-1 Pathogenesis of Obesity (T3L3)
Michael Jardine
PHSI3012 13-1 Sarcopenia (T3L7)
Michael Jardine